On Wednesday October 19, The Medical Device Innovation Consortium (MDIC) announced its partnership with PerkinElmer’s Horizon Discovery to develop and manufacture somatic reference samples (SRSs) to simplify and support the validation of NGS-based cancer diagnostics.
The SRSs are expected to be commercially available by early 2024, developed by Horizon, and in collaboration with the National Institute for Standards and Technology (NIST).
“Helping improve cancer testing, and in-turn patient treatment, is a focus for many of us at Horizon Discovery. The Company’s reference standards have been critical enablers in research for a variety of diseases, and now we look forward to partnering with MDIC to bring standards to the oncology community.” Bryan Kipp, VP/GM Life Science Strategy & Integration, PerkinElmer
Horizon will engineer and manufacture ten SRSs, each with a variant associated with a certain cancer type identified by an extensive study completed by MDIC in 2019. The variants span a range of cancers and variant types to offer as broad validation as possible.